Author

Zhenzhen Yin

Observed names: Z M Yin, Z. Yin

Institutions: Harvard University, Massachusetts General Hospital

Observed institutions: Harvard University, Tianjin Medical University Cancer Institute and Hospital, Massachusetts General Hospital, Tianjin Medical University

ORCID: 0000-0002-6022-5661

Observed ORCID: 0000-0002-6022-5661

OpenAlex ID: A5102000202

Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models

2021 · Limeng Wu, Sasa Vasilijic, et al. · Science Translational Medicine · 52

Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer

2024 · Yao Sun, Zhenzhen Yin, et al. · British Journal of Cancer · 22

Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma

2023 · Srirupa Bhattacharyya, Janet L Oblinger, et al. · Neuro-Oncology · 10

Effects and toxicity of neoadjuvant chemotherapy preoperative followed by adjuvant chemoradiation in small cell neurdendocrine cervical carcinoma.

2015 · Z M Yin, A J Yu, et al. · PubMed · 9

NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss

2026 · Simeng Lu, Zhenzhen Yin, et al. · Nature Communications · 8

Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis

2024 · Simeng Lu, Zhenzhen Yin, et al. · Cancers · 6

Prognostic factors and treatment comparison in small cell neuroendocrine cervical carcinoma.

2014 · Z M Yin, A J Yu, et al. · PubMed · 6

Co-Targeting IL-6 and EGFR signaling for the treatment of schwannomatosis and associated pain

2023 · Zhenzhen Yin, Limeng Wu, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 5

The Prevalence and Prognostic Value of p16 in Non-Oropharyngeal Head and Neck Squamous Cell Carcinoma

2019 · X. Wang, Z. Yin, et al. · International Journal of Radiation Oncology*Biology*Physics · 2

Addition of Losartan to Immune Checkpoint Blockade Improves Tumor Control and Neurological Outcomes in Models of NF2-Related Schwannomatosis

2026 · Simeng Lu, Jie Chen, et al. · Cellular and Molecular Bioengineering

Deciphering and Targeting the Schwannoma‐Neuron‐Macrophage Crosstalk for the Treatment of Schwannomatosis and Associated Pain

2026 · Zhenzhen Yin, Limeng Wu, et al. · Advanced Science

Direct and abscopal anti-tumor responses elicited by peripheral nerve schwannoma irradiation synergize with anti-PD1 treatment in vestibular schwannoma models

2024 · Zhenzhen Yin, Simeng Lu, et al. · bioRxiv (Cold Spring Harbor Laboratory)

314 (PB302): Deciphering and targeting the schwannoma-neuron-macrophage crosstalk for the treatment of schwannomatosis and associated pain

2024 · Z. Yin, J. Chen, et al. · European Journal of Cancer

Abstract A104: Losartan rewires ovarian cancer tumor-immune microenvironment and suppresses IGF-1 to amplify chemo-immunotherapy sensitivity

2024 · Yao Sun, Zhenzhen Yin, et al. · Cancer Research

1040-E Deciphering and targeting the schwannoma-neuron-macrophage crosstalk for the treatment of schwannomatosis and associated pain

2023 · Zhenzhen Yin, Limeng Wu, et al. · Journal for ImmunoTherapy of Cancer

Works count: 15

Citation count: 120

H-index: 6

I10-index: 3